| Product Name | IL35 ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Interleukin 35 (IL35). No significant cross-reactivity or interference between Interleukin 35 (IL35) and analogues was observed. |
| Method | Sandwich |
| Detection Range | 15.6-1,000pg/mL |
| Sensitivity | 5.8pg/mL |
| Target | IL35 |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Interleukin 35 (IL35). No significant cross-reactivity or interference between Interleukin 35 (IL35) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia.;Plasma IL-17, IL-35, interferon-γ, SOCS3 and TGF-β levels in pregnant women with preeclampsia, and their relation with severity of disease;What is the impact of Th1/Th2 ratio, SOCS3, IL17, and IL35 levels in unexplained infertility?;The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia;Gene Expression of Subunits of the IL-12 Family Cytokines in moDCs Derived In Vitro from the Cord Blood of Children of Healthy and Allergic Mothers;Function of interleukin?17 and ?35 in the blood of patients with hepatitis B?related liver cirrhosis;Wogonin Inhibits Tumor-derived Regulatory Molecules by Suppressing STAT3 Signaling to Promote Tumor Immunity;Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis;Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease;Anti-inflammatory effects of interleukin-35 in acquired aplastic anemia;Interleukin 35 may contribute to the loss of immunological self‐tolerance in patients with primary immune thrombocytopenia;New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature;Increased plasma concentrations of interleukin 35 in patients with coronary artery disease;The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis;Enhanced LPS-induced activation of IL-27 signalling in sarcoidosis;IL-35;Upregulation of Interleukin 35 in Patients With Endometriosis Stimulates Cell Proliferation;IL‑35 may maintain homeostasis of the immune microenvironment in periodontitis;Synoviocytes-derived Interleukin 35 Potentiates B Cell Response in Patients with Osteoarthritis and Rheumatoid Arthritis;Human immunodeficiency virus type-1 induces a regulatory B cell-like phenotype in vitro;Lower level of IL‑35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs test‑positive hemocytopenia.;Evaluation of serum interleukin- 35 level in children with persistent asthma.;Significant association between FOXP3 gene polymorphism and steroid-resistant acute rejection in living donor liver transplantation;Clinical significance of IL-35 expression in the progression of clear cell renal cell carcinoma ;Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy.;AB0734 Serum il-35 levels in systemic sclerosis and relationship with clinical features;Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients;The impact of plasma SOCS3 levels and endometrial leukocytes on unexplained infertility;Serum Interleukin 35 Levels in Systemic Sclerosis and Relationship With Clinical Features.;Interleukin‑35 is associated with the tumorigenesis and progression of prostate cancer;CD4+ FOXP3+ T Cells in Rheumatoid Arthritis Bone Marrow Are Partially Impaired;Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity;Interleukin-9 regulates macrophage activation in the progressive multiple sclerosis brain;Association of IL-35 expression and gene polymorphisms in rheumatoid arthritis;Decreased interleukin-35 levels and CD4+ EBI3+ T cells in patients with type 1 diabetes and the effects of the antibody against CD20 (rituximab);Anti-inflammatory roles of interleukin-35 in the pathogenesis of Japanese cedar pollinosis;Association of three single nucleotide polymorphisms of interleukin-35 for detection and prediction of women with breast cancer in Erbil city;Analysis of IL-10 and IL-35 in DPP-4 inhibitor-related bullous pemphigoid; |
| Supplier | Cloud Clone |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.